<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETHAMBUTOL HYDROCHLORIDE</span><br/>(e-tham'byoo-tole)<br/><span class="topboxtradename">Etibi <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Myambutol<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antituberculosis agent</span><br/><b>Prototype: </b>Isoniazid<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Mode of action not completely understood, but it appears to inhibit RNA synthesis and thus arrests multiplication of tubercle
         bacilli. The emergence of resistant strains is delayed by administering ethambutol in combination with other antituberculosis
         drugs.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Synthetic antituberculosis agent with bacteriostatic effect.</p>
<h1><a name="uses">Uses</a></h1>
<p>In conjunction with at least one other antituberculosis agent in treatment of pulmonary tuberculosis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Atypical mycobacterial infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Optic neuritis; hypersensitivity to ethambutol; optic neuritis, patients unable to report changes in vision (young children,
         or unconscious patients); children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, hepatic disease; gout; ocular defects (e.g., cataract, recurrent ocular inflammatory conditions, diabetic
         retinopathy); pregnancy (category B), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tuberculosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg/kg q24h; for retreatment start with 25 mg/kg/d for 60 d, then decrease to 15 mg/kg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>612 y</i>, 1015 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food if GI irritation occurs.</li>
<li>Protect ethambutol from light, moisture, and excessive heat. Store at 15°30° C (59°86° F)
            in tightly closed container unless otherwise directed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, confusion, hallucinations, paresthesias, joint pains. <span class="typehead">Special Senses:</span> Ocular toxicity: <span class="speceff-common">retrobulbar optic neuritis;</span> possibility of anterior optic neuritis with decrease in visual acuity, temporary loss of vision, constriction of visual fields,
      redgreen color blindness, central and peripheral scotomas, eye pain, photophobia; retinal hemorrhage and edema. <span class="typehead"> GI:</span> Anorexia, nausea, vomiting, abdominal pain. <span class="typehead">Body as a Whole:</span> Hypersensitivity (pruritus, dermatitis, <span class="speceff-life">anaphylaxis</span>). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aluminum-containing antacids</b> can decrease absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 7080% absorbed from GI tract. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> Distributes to most body tissues; highest concentrations in erythrocytes, kidney, lungs, saliva; crosses placenta; distributed
      into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 50% excreted in urine within 24 h; 2022% excreted in feces. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Perform C&amp;S prior to and periodically throughout therapy.</li>
<li>Perform ophthalmoscopic examination prior to and at monthly intervals during therapy. Test eyes separately as well as together.</li>
<li>
            							Note: Ocular toxicity generally appears within 17 mo after start of therapy. Symptoms usually disappear within several weeks
            to months after drug is discontinued, depending on degree of ocular damage.
            						
         </li>
<li>Monitor I&amp;O ratio in patients with renal impairment. Report oliguria or any significant changes in ratio or in laboratory
            reports of kidney function. Systemic accumulation with toxicity can result from delayed drug excretion.
         </li>
<li>Lab tests: Perform liver and kidney function tests, CBC, and serum uric acid levels at regular intervals throughout therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Adhere to drug regimen exactly and keep follow-up appointments.</li>
<li>Notify physician promptly of the onset of blurred vision, changes in color perception, constriction of visual fields, or any
            other visual symptoms. Have eyes checked periodically. Ethambutol can cause irreversible blindness due to optic neuritis.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>